Unnamed: 0,title,date,stock,sentiment
1060875.0,uniQure Highlights Presentations For ASGCT Meeting,2020-05-14 07:12:00-04:00,QURE,neutral
1060876.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,QURE,negative
1060877.0,uniQure Q1 EPS $(0.630) Up From $(0.740) YoY,2020-04-29 07:11:00-04:00,QURE,neutral
1060878.0,uniQure Shares Volatile On Uptick In Volume; Hearing Cantor Fitzgerald Out With Positive Comments On Name,2020-04-24 13:49:00-04:00,QURE,positive
1060879.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,QURE,positive
1060880.0,uniQure Reports Achievement Of Target Patient Dosing In HOPE-B Trial Of AMT-061 For Hemophilia B,2020-03-26 07:30:00-04:00,QURE,neutral
1060881.0,Shares of several healthcare  companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.,2020-03-09 10:55:00-04:00,QURE,neutral
1060882.0,Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.,2020-03-06 09:11:00-05:00,QURE,neutral
1060883.0,"Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $105",2020-03-03 10:37:00-05:00,QURE,negative
1060884.0,uniQure And Gen-X Enter Research Collaboration And License Agreement For The Development Of Novel Synthetic Promoters,2020-03-02 16:15:00-05:00,QURE,positive
1060885.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,QURE,negative
1060886.0,"Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to $96",2020-01-23 08:15:00-05:00,QURE,negative
1060887.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,QURE,neutral
1060888.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,QURE,neutral
1060889.0,uniQure Option Alert: Jan 17 $80 Calls Sweep (4) above Ask!: 575 @ $2.75 vs 1546 OI; Ref=$70.45,2019-12-18 12:55:00-05:00,QURE,positive
1060890.0,10 Biggest Price Target Changes For Tuesday,2019-12-10 08:42:00-05:00,QURE,neutral
1060891.0,"Mizuho Reiterates Buy on uniQure, Raises Price Target to $90",2019-12-10 08:01:00-05:00,QURE,neutral
1060892.0,uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B at ASH 2019,2019-12-08 16:06:00-05:00,QURE,neutral
1060893.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,QURE,positive
1060894.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,QURE,neutral
1060895.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-12-03 12:20:00-05:00,QURE,neutral
1060896.0,The Gene Therapy Names Moving On The Audentes Buyout Deal,2019-12-03 11:53:00-05:00,QURE,neutral
1060897.0,UniQure shares are trading higher following the acquisition of gene therapy peer Audentes Therapeutics by Astellas.,2019-12-03 10:56:00-05:00,QURE,positive
1060898.0,"Benzinga's Top Upgrades, Downgrades For December 3, 2019",2019-12-03 09:35:00-05:00,QURE,positive
1060899.0,UniQure NV shares are trading higher after analysts from Goldman Sachs and Cowen & Co initiated coverage on the company's stock with bullish ratings.,2019-12-03 07:52:00-05:00,QURE,positive
1060900.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-03 07:46:00-05:00,QURE,neutral
1060901.0,22 Stocks Moving in Tuesday's Pre-Market Session,2019-12-03 07:26:00-05:00,QURE,neutral
1060902.0,Cowen & Co. Initiates Coverage On uniQure with Outperform Rating,2019-12-03 07:12:00-05:00,QURE,neutral
1060903.0,"Goldman Sachs Initiates Coverage On uniQure with Buy Rating, Announces $98 Price Target",2019-12-03 07:09:00-05:00,QURE,neutral
1060904.0,"Benzinga's Top Upgrades, Downgrades For November 5, 2019",2019-11-05 10:00:00-05:00,QURE,positive
1060905.0,uniQure Announces The Allowance Of New Patent Providing Further Protection Of The Padua And Padua-Related Variants Of Factor IX In Gene Therapy,2019-11-05 07:18:00-05:00,QURE,neutral
1060906.0,"Credit Suisse Initiates Coverage On uniQure with Outperform Rating, Announces $76 Price Target",2019-11-05 07:16:00-05:00,QURE,positive
1060907.0,uniQure Highlights Publication Of Interim Data From Phase IIb Clinical Trial Of Etranacogene Dezaparvovec,2019-10-31 09:20:00-04:00,QURE,neutral
1060908.0,"Benzinga's Top Upgrades, Downgrades For October 11, 2019",2019-10-11 10:10:00-04:00,QURE,positive
1060909.0,"Stifel Nicolaus Initiates Coverage On uniQure with Buy Rating, Announces $79 Price Target",2019-10-11 07:12:00-04:00,QURE,neutral
1060910.0,"Benzinga's Top Upgrades, Downgrades For September 25, 2019",2019-09-25 10:04:00-04:00,QURE,positive
1060911.0,"Bernstein Initiates Coverage On uniQure with Outperform Rating, Announces $73 Price Target",2019-09-25 07:01:00-04:00,QURE,neutral
1060912.0,"Mizuho Initiates Coverage On uniQure with Buy Rating, Announces $67 Price Target",2019-09-12 06:55:00-04:00,QURE,neutral
1060913.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-06 08:31:00-04:00,QURE,neutral
1060914.0,86 Biggest Movers From Yesterday,2019-09-06 05:06:00-04:00,QURE,negative
1060915.0,uniQure Prices 4.9M Share  Public Offering @$46/Share,2019-09-06 04:45:00-04:00,QURE,positive
1060916.0,55 Stocks Moving In Thursday's Mid-Day Session,2019-09-05 12:27:00-04:00,QURE,neutral
1060917.0,UniQure shares are trading lower after the company reported a $200 million common stock offering.,2019-09-05 09:33:00-04:00,QURE,neutral
1060918.0,"The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug",2019-09-05 08:12:00-04:00,QURE,neutral
1060919.0,UniQure shares are trading lower after the company reported a $200 million common stock offering.,2019-09-04 16:05:00-04:00,QURE,neutral
1060920.0,uniQure Reports $200M Common Stock Offering,2019-09-04 16:03:00-04:00,QURE,neutral
1060921.0,uniQure Achieves Planned Enrollment In HOPE-B Pivotal Trial Of AMT-061 In Patients With Hemophilia B,2019-09-03 07:08:00-04:00,QURE,neutral
1060922.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,QURE,positive
1060923.0,"Benzinga's Top Upgrades, Downgrades For July 30, 2019",2019-07-30 09:59:00-04:00,QURE,positive
1060924.0,Guggenheim Downgrades uniQure to Neutral,2019-07-30 06:42:00-04:00,QURE,neutral
1060925.0,"uniQure Q2 EPS $(0.83) Misses $(0.75) Estimate, Sales $2.47M Beat $1.46M Estimate",2019-07-29 07:25:00-04:00,QURE,negative
1060926.0,uniQure Option Alert: Jan 17 $70 Calls Sweep (2) near the Ask: 600 @ $14.351 vs 19 OI; Earnings 8/7 Before Open [est] Ref=$68.48,2019-07-15 12:31:00-04:00,QURE,positive
1060927.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,QURE,positive
1060928.0,uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061; Clinical Benefit and Tolerability Maintained in All Patients Through Up to 3.5 Years of Follow-up,2019-07-06 07:36:00-04:00,QURE,positive
1060929.0,"The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight",2019-07-05 08:55:00-04:00,QURE,negative
1060930.0,The Week Ahead In Biotech: Pending Clinical Readouts In Focus,2019-06-29 08:25:00-04:00,QURE,neutral
1060931.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,QURE,neutral
1060932.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,QURE,neutral
1060933.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,QURE,neutral
1060934.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,QURE,neutral
1060935.0,44 Stocks Moving In Monday's Mid-Day Session,2019-06-17 12:23:00-04:00,QURE,neutral
1060936.0,28 Stocks Moving In Monday's Pre-Market Session,2019-06-17 08:06:00-04:00,QURE,neutral
1060937.0,Report: uniQure Could Put Itself Up For Sale,2019-06-17 07:40:00-04:00,QURE,neutral
1060938.0,"UniQure shares are trading higher following a media report that the company is exploring strategic options, including a potential sale.",2019-06-17 06:59:00-04:00,QURE,positive
1060939.0,A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data,2019-06-17 06:37:00-04:00,QURE,neutral
1060940.0,"5 Stocks To Watch For June 17, 2019",2019-06-17 05:49:00-04:00,QURE,neutral
1060941.0,uniQure Shares Rise 9% Premarket to $79 Following Bloomberg Report Company Exploring Options Including Potential Sale,2019-06-17 04:47:00-04:00,QURE,positive
1060942.0,Gene-Therapy Firm UniQure Explores Options Including Sale,2019-06-16 19:10:00-04:00,QURE,neutral
1060943.0,66 Biggest Movers From Yesterday,2019-06-12 04:44:00-04:00,QURE,neutral
1060944.0,uniQure shares are trading lower despite no clear catalyst to justify price action. One analyst suggested downside may be due to profit taking following recent strength.,2019-06-11 14:06:00-04:00,QURE,positive
1060945.0,"Janney Reiterates Buy On uniQure As Firm 'Would Be Buyers On Today's Weakness' As Firm Believes Co.  Should Have 'the first FDA approval for an AAV gene therapy for hemophilia B, 2) the first AAV gene therapy program in the clinic for Huntingon's'",2019-06-11 14:06:00-04:00,QURE,positive
1060946.0,48 Stocks Moving In Tuesday's Mid-Day Session,2019-06-11 12:36:00-04:00,QURE,neutral
1060947.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,QURE,neutral
1060948.0,4 Momentum Stocks To Watch,2019-06-05 13:56:00-04:00,QURE,neutral
1060949.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,QURE,positive
1060950.0,Adam Feuerstein Tweet: I call b******t. Do you people know where Goldman holds this conference? No one cancels for a schedule conflict,2019-06-04 20:43:00-04:00,QURE,negative
1060951.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,QURE,positive
1060952.0,"Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.",2019-06-03 09:32:00-04:00,QURE,positive
1060953.0,Shares of several companies in the healthcare sector are trading lower. Not seeing any news to justify this price action.,2019-05-22 15:07:00-04:00,QURE,neutral
1060954.0,uniQure Reports Was Issued 2 New Patents Covering AMT-130,2019-05-22 07:04:00-04:00,QURE,neutral
1060955.0,uniQure shares trading higher following news the company presented data from a Phase IIb study of AMT-061 in patients with hemophilia B.,2019-05-10 13:59:00-04:00,QURE,positive
1060956.0,uniQure Highlights Presentation Of Data From Phase IIb Study Of AMT-061 In Patients With Hemophilia B,2019-05-10 08:08:00-04:00,QURE,neutral
1060957.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,QURE,negative
1060958.0,Uniqure Will Present Today New Preclinical Data On Its Gene Therapy Candidates Amt-180 For The Treatment Of Hemophilia A And Amt-190 For The Treatment Of Fabry Disease,2019-05-02 08:56:00-04:00,QURE,neutral
1060959.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,QURE,negative
1060960.0,"uniQure Q1 EPS $(0.74) Misses $(0.71) Estimate, Sales $1.136M Miss $2.05M Estimate",2019-04-29 07:01:00-04:00,QURE,negative
1060961.0,"PiperJaffray Initiates Coverage On uniQure with Overweight Rating, Announces $80 Price Target",2019-04-12 07:23:00-04:00,QURE,negative
1060962.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-04-08 07:32:00-04:00,QURE,negative
1060963.0,uniQure Reports FDA Fast Track Designation For AMT-130 Gene Therapy For Treatment Of Huntington's Disease,2019-04-08 07:13:00-04:00,QURE,neutral
1060964.0,"Benzinga's Top Upgrades, Downgrades For March 29, 2019",2019-03-29 09:11:00-04:00,QURE,positive
1060965.0,"Baird Initiates Coverage On uniQure with Outperform Rating, Announces $85 Price Target",2019-03-29 06:54:00-04:00,QURE,neutral
1060966.0,6 Gene Therapy M&A Targets On The Radar,2019-03-27 12:45:00-04:00,QURE,neutral
1060967.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,QURE,negative
1060968.0,"CORRECTION: Wells Fargo Maintained Outperform Rating On uniQure, Raised Price Target From $65 To $90; Initial headline suggested the price target was lowered; this was incorrect",2019-03-15 10:11:00-04:00,QURE,positive
1060969.0,"Wells Fargo Maintains Outperform on uniQure, Raises Price Target to $90",2019-03-15 09:59:00-04:00,QURE,positive
1060970.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,QURE,positive
1060971.0,"The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings",2019-03-08 07:38:00-05:00,QURE,neutral
1060972.0,"Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.",2019-03-06 11:59:00-05:00,QURE,negative
1060973.0,"uniQure BV Q3 EPS $(0.59) Beats $(0.62) Estimate, Sales $3.148M Beat $2.81M Estimate",2019-02-28 07:21:00-05:00,QURE,neutral
1060974.0,uniQure Highlights Presentation Of New Preclinical Data On AMT-130 At The CHDI's 14th Annual Huntington's Disease Therapeutics Conference,2019-02-27 07:29:00-05:00,QURE,neutral
1060975.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,QURE,positive
1060976.0,72 Biggest Movers From Yesterday,2019-02-26 05:31:00-05:00,QURE,neutral
1060977.0,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,2019-02-25 15:12:00-05:00,QURE,positive
1060978.0,42 Stocks Moving In Monday's Mid-Day Session,2019-02-25 12:25:00-05:00,QURE,neutral
1060979.0,Mid-Morning Market Update: Markets Open Higher; Roche To Acquire Spark Therapeutics For $114.50/Share,2019-02-25 10:16:00-05:00,QURE,positive
1060980.0,"Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to $81",2019-02-25 09:44:00-05:00,QURE,negative
1060981.0,Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for $114.50 per share in cash.,2019-02-25 09:38:00-05:00,QURE,positive
1060982.0,28 Stocks Moving In Monday's Pre-Market Session,2019-02-25 08:00:00-05:00,QURE,neutral
1060983.0,66 Biggest Movers From Friday,2019-02-11 04:33:00-05:00,QURE,neutral
1060984.0,48 Stocks Moving In Friday's Mid-Day Session,2019-02-08 12:42:00-05:00,QURE,neutral
1060985.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,QURE,negative
1060986.0,uniQure Offers Updated Clinical Data From Phase IIb Study Of AMT-061 In Patients With Hemophilia B,2019-02-08 07:06:00-05:00,QURE,neutral
1060987.0,uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B,2019-02-04 07:09:00-05:00,QURE,neutral
1060988.0,Uniqure Announces FDA Clearance Of Investigational New Drug Application For Amt-130 In Huntington's Disease,2019-01-22 07:01:00-05:00,QURE,neutral
1060989.0,"Benzinga's Top Upgrades, Downgrades For December 31, 2018",2018-12-31 09:18:00-05:00,QURE,positive
1060990.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Nov. 16, 2018",2018-11-16 11:18:00-05:00,QURE,positive
1060991.0,"B. Riley FBR Maintains Buy on uniQure, Raises Price Target to $72",2018-11-16 11:06:00-05:00,QURE,neutral
1060992.0,64 Biggest Movers From Yesterday,2018-11-16 04:58:00-05:00,QURE,neutral
1060993.0,Mid-Afternoon Market Update: Dow Up 240 Points; Uniqure Shares Spike Higher,2018-11-15 14:42:00-05:00,QURE,positive
1060994.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-11-15 12:38:00-05:00,QURE,neutral
1060995.0,Mid-Day Market Update: Smart & Final Stores Rises Following Strong Q3 Earnings; Remark Holdings Shares Drop,2018-11-15 12:09:00-05:00,QURE,positive
1060996.0,UniQure NV shares are up 49.3% after the company reported all hemophilia patients in its dose-combo study of AMT-061 achieved a positive response.,2018-11-15 11:05:00-05:00,QURE,positive
1060997.0,Mid-Morning Market Update: Markets Open Lower; Walmart Profit Tops Expectations,2018-11-15 10:21:00-05:00,QURE,positive
1060998.0,uniQure Offers Initial Top-Line Data From Dose-Combo Study Of AMT-061 In Patients With Hemophilia B: 'All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31%',2018-11-15 07:14:00-05:00,QURE,neutral
1060999.0,"uniQure BV Q3 EPS $(0.59) Beats $(0.62) Estimate, Sales $3.148M Beat $2.81M Estimate",2018-11-06 07:03:00-05:00,QURE,neutral
1061000.0,"H.C. Wainwright Maintains Buy on uniQure, Raises Price Target to $48",2018-09-24 09:33:00-04:00,QURE,neutral
1061001.0,uniQure Announces a Third Patient Treated in its Phase IIb Study of AMT-061,2018-09-24 07:07:00-04:00,QURE,neutral
1061002.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,QURE,neutral
1061003.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,QURE,neutral
1061004.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,QURE,positive
1061005.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,QURE,neutral
1061006.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,QURE,neutral
1061007.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,QURE,neutral
1061008.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,QURE,neutral
1061009.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,QURE,neutral
1061010.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,QURE,positive
1061011.0,"uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B, Expects Topline Data In Q4 2018",2018-08-23 07:02:00-04:00,QURE,neutral
1061012.0,"uniQure Q2 EPS $(0.57) Beats $(0.61) Estimate, Sales $3.1M Beat $2.87M Estimate",2018-08-08 07:19:00-04:00,QURE,neutral
1061013.0,"Benzinga's Top Upgrades, Downgrades For July 27, 2018",2018-07-27 09:17:00-04:00,QURE,positive
1061014.0,"Cantor Fitzgerald Initiates Coverage On uniQure with Overweight Rating, Announces $58 Price Target",2018-07-27 08:08:00-04:00,QURE,negative
1061015.0,40 Biggest Movers From Yesterday,2018-07-17 04:50:00-04:00,QURE,neutral
1061016.0,48 Biggest Movers From Yesterday,2018-06-29 04:06:00-04:00,QURE,neutral
1061017.0,3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy,2018-06-28 15:18:00-04:00,QURE,neutral
1061018.0,"B. Riley FBR Initiates Coverage On uniQure with Buy Rating, Announces $50 Price Target",2018-06-28 08:14:00-04:00,QURE,neutral
1061019.0,uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B,2018-06-28 07:08:00-04:00,QURE,neutral
1061020.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,QURE,neutral
1061021.0,"uniQure Files For Potential Mixed Shelf Offering, No Size Disclosed",2018-06-14 16:46:00-04:00,QURE,negative
1061022.0,44 Biggest Movers From Yesterday,2018-06-12 04:49:00-04:00,QURE,neutral
1061023.0,"uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy, Additional Issued Patent Covering Manufacturing Further Strengthens Intellectual Property Portfolio",2018-05-29 07:01:00-04:00,QURE,positive
1061024.0,"SunTrust Robinson Humphrey Initiates Coverage On uniQure with Buy Rating, Announces $48 Price Target",2018-05-24 07:10:00-04:00,QURE,neutral
1061025.0,uniQure Presents Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies,2018-05-21 07:03:00-04:00,QURE,positive
1061026.0,Uniqure Notches Bullish Initiation On Gene Therapy Prospects,2018-05-20 16:38:00-04:00,QURE,positive
1061027.0,"Wells Fargo Initiates Coverage On uniQure with Outperform Rating, Announces $47 Price Target",2018-05-16 08:12:00-04:00,QURE,positive
1061028.0,UniQure Prices 4.5M Share Offering @$28.50/Share,2018-05-02 19:36:00-04:00,QURE,positive
1061029.0,uniQure Announces 4M Common Share Offering,2018-05-01 16:04:00-04:00,QURE,positive
1061030.0,"uniQure Reports Q1 EPS $(0.59) Beats $(0.74) Est., Sales $3.48M Beats $2.82M Est.",2018-04-30 07:11:00-04:00,QURE,neutral
1061031.0,"uniQure Offers Preclinical Data On AMT-130 In Huntington's Disease, Showed Single Intraparenchymal Administration Of AMT-130 In Striatum Resulted In Dose-Dependent, Sustained Reduction Of mHTT In Both Deep Structures Of Brain",2018-04-25 16:57:00-04:00,QURE,neutral
1061032.0,Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure,2018-04-24 10:49:00-04:00,QURE,positive
1061033.0,40 Biggest Movers From Yesterday,2018-04-10 04:21:00-04:00,QURE,neutral
1061034.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-09 12:32:00-04:00,QURE,neutral
1061035.0,Janney: Buy The Dip In Uniqure,2018-03-20 11:39:00-04:00,QURE,neutral
1061036.0,"Janney On uniQure: 'Buy On Weakness'; Fair Value Target Raised From $25 To $30, AMT-130 For HD Added To Valuation",2018-03-20 09:20:00-04:00,QURE,positive
1061037.0,"uniQure Reports FY EPS $(2.94) vs $(2.88) Est., Sales $13.11M vs $12.64M Est.",2018-03-14 07:02:00-04:00,QURE,neutral
1061038.0,uniQure Reports FY17 EPS $(2.94) vs $(2.93) In Prior Year,2018-03-14 07:01:00-04:00,QURE,neutral
1061039.0,uniQure Spikes to High of $22.59; Co Presenting Today at SunTrust 4th Annual Orphan Drug Day,2018-02-13 11:22:00-05:00,QURE,neutral
1061040.0,33 Biggest Movers From Yesterday,2018-02-13 05:05:00-05:00,QURE,neutral
1061041.0,"UPDATE: uniQure Shares Continue to Spike Higher; Co Also Presenting at Leerink Global Healthcare Conference on February 14, 15",2018-02-12 14:13:00-05:00,QURE,positive
1061042.0,"uniQure Spikes to High of $20.46; Co to Present Tomorrow at SunTrust 4th Annual Orphan Drug Day, February 13, 2018 in New York City",2018-02-12 13:59:00-05:00,QURE,neutral
1061043.0,38 Biggest Movers From Yesterday,2018-01-23 04:55:00-05:00,QURE,neutral
1061044.0,32 Stocks Moving In Monday's Mid-Day Session,2018-01-22 12:46:00-05:00,QURE,neutral
1061045.0,30 Stocks Moving In Monday's Pre-Market Session,2018-01-22 07:58:00-05:00,QURE,neutral
1061046.0,uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease,2018-01-22 07:02:00-05:00,QURE,neutral
1061047.0,"uniQure Shares Down 7% Mon.; Co. Earlier Outlined Near-Term Objectives: 'Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End'",2018-01-08 11:49:00-05:00,QURE,positive
1061048.0,"Janney Capital Initiates Coverage On uniQure with Buy Rating, Announces $25.00 Price Target",2018-01-04 07:33:00-05:00,QURE,neutral
1061049.0,"uniQure Reports Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds, with No Confirmed Bleeds Reported in Last 12 Mo.; Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity At Up To 2 Years Follow Up",2017-12-11 07:03:00-05:00,QURE,positive
1061050.0,uniQure Announces Presentation of Non-Clinical Data of AMT-061 at #ASH2017,2017-12-09 14:51:00-05:00,QURE,neutral
1061051.0,Uniqure Option Alert: Jan 19 $17.5 Calls at the Ask: 2500 @ $2.0 vs 141 OI; Ref=$17.32,2017-12-08 13:39:00-05:00,QURE,positive
1061052.0,uniQure Shares Up 11.67% On No Apparent News,2017-12-07 15:53:00-05:00,QURE,neutral
1061053.0,25 Stocks Moving In Friday's Mid-Day Session,2017-12-01 12:46:00-05:00,QURE,neutral
1061054.0,"Benzinga's Top Upgrades, Downgrades For December 1, 2017",2017-12-01 09:11:00-05:00,QURE,positive
1061055.0,"H.C. Wainwright Initiates Coverage On uniQure NV with Buy Rating, Announces $28.00 Price Target",2017-12-01 07:13:00-05:00,QURE,neutral
1061056.0,uniQure Shares Spike Higher To Afternoon Highs As Leerink Mid-Day Comments Showed Raised Price Target To $26,2017-11-07 14:44:00-05:00,QURE,positive
1061057.0,"Evercore ISI Group Initiates Coverage On uniQure NV with Outperform Rating, Announces $22.00 Price Target",2017-11-07 09:30:00-05:00,QURE,neutral
1061058.0,uniQure 13G From Foresite Capital Fund Shows 5.5% Stake,2017-11-03 13:06:00-04:00,QURE,neutral
1061059.0,"uniQure Reports Q3 EPS $(0.40) vs $(0.64) Est., Sales $2.3M vs $6.3M Est.",2017-11-01 07:09:00-04:00,QURE,neutral
1061060.0,uniQure Prices 5M Share Public Offering @$18.25/Share,2017-10-25 03:53:00-04:00,QURE,positive
1061061.0,Benzinga's Option Alert Recap From October 24,2017-10-24 16:39:00-04:00,QURE,positive
1061062.0,33 Stocks Moving In Tuesday's Mid-Day Session,2017-10-24 12:50:00-04:00,QURE,neutral
1061063.0,UniQure Option Alert: Nov 17 $22.5 Calls Sweep (19) at the Bid: 601 @ $0.7 vs 72 OI; Ref=$19.05,2017-10-24 11:25:00-04:00,QURE,positive
1061064.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-10-24 08:08:00-04:00,QURE,neutral
1061065.0,uniQure Reports Offering Of 5M Shares Of Common Stock,2017-10-23 16:06:00-04:00,QURE,positive
1061066.0,"Uniqure Shares Turn Positve Over Last Few Mins., Breaking Above $19 Resistance Level; Stock Up 1.8% For Session, Flirting With $20 Level",2017-10-23 12:06:00-04:00,QURE,positive
1061067.0,35 Biggest Movers From Friday,2017-10-23 06:07:00-04:00,QURE,neutral
1061068.0,There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials,2017-10-20 13:53:00-04:00,QURE,neutral
1061069.0,32 Stocks Moving In Friday's Mid-Day Session,2017-10-20 12:27:00-04:00,QURE,neutral
1061070.0,"Wall Street's M&A Chatter From October 19: Uniqure, Ulta, Sally Beauty, Tribune -Sinclair",2017-10-20 08:16:00-04:00,QURE,positive
1061071.0,25 Stocks Moving In Friday's Pre-Market Session,2017-10-20 08:03:00-04:00,QURE,neutral
1061072.0,38 Biggest Movers From Yesterday,2017-10-20 06:21:00-04:00,QURE,neutral
1061073.0,Mid-Afternoon Market Update: Crude Oil Down 1.25%; Alcobra Shares Spike Higher,2017-10-19 14:30:00-04:00,QURE,negative
1061074.0,32 Stocks Moving In Thursday's Mid-Day Session,2017-10-19 12:59:00-04:00,QURE,neutral
1061075.0,Mid-Day Market Update: Heritage-Crystal Clean Drops On Weak Q3 Results; Imprimis Pharmaceuticals Shares Surge,2017-10-19 12:37:00-04:00,QURE,positive
1061076.0,"Oppenheimer Out Positive On uniQure, Says Acquisition of AMT-061 Was Astute, Believes Product Has Potentially 6-7 Times The Well-Known Fix Expression Levels Of AMT-060; Believes It's A Potentially Significant Benefit To Hemophilia Patients",2017-10-19 11:27:00-04:00,QURE,positive
1061077.0,uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX,2017-10-19 07:11:00-04:00,QURE,positive
1061078.0,38 Biggest Movers From Yesterday,2017-10-19 04:45:00-04:00,QURE,neutral
1061079.0,32 Stocks Moving In Wednesday's Mid-Day Session,2017-10-18 12:53:00-04:00,QURE,neutral
1061080.0,UPDATE: uniQure Reports IND-Enabling Toxicology Study Initiated,2017-10-18 07:09:00-04:00,QURE,neutral
1061081.0,uniQure To Offer Preclinical Data On AMT-130 In Huntington's Disease At ESGCT Congress: Highlights 1-Time Administration Showed 'Survival Benefit and Functional Improvement of Huntington's Disease Symptoms in Preclinical Study',2017-10-18 07:09:00-04:00,QURE,positive
1061082.0,A Peek Into The Markets: U.S. Stock Futures Mostly Flat; All Eyes On Jobs Data,2017-10-06 07:09:00-04:00,QURE,neutral
1061083.0,uniQure Granted Orphan Drug Designation for AMT-130 by the FDA,2017-10-06 07:00:00-04:00,QURE,positive
1061084.0,"Companies Holding Shareholder Meetings Today Include: AMREP, Bovie Medical, Dorial LPG, Ellomay Capital, H&R Block, Interpace Diagnostics Group, Methode Electronics, NetApp, PhotoMedex, StealthGas, STRATA Skin Sciences, and uniQure",2017-09-14 09:00:00-04:00,QURE,negative
1061085.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-28 08:16:00-04:00,QURE,neutral
1061086.0,"uniQure Q2 EPS $(0.83) vs $(0.80) Est., Sales $4.9M vs $2.6M Est.",2017-08-08 07:30:00-04:00,QURE,neutral
1061087.0,uniQure Announces Scot McMillan COO,2017-08-07 07:22:00-04:00,QURE,neutral
1061088.0,uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate for Hemophilia B,2017-07-31 07:20:00-04:00,QURE,neutral
1061089.0,uniQure Granted Patent Protecting Insect Cell-Based AAV Manufacturing,2017-07-18 07:05:00-04:00,QURE,positive
1061090.0,uniQure Says New Data Supports Expanding Eligibility of AAV5 to Hemophilia B Patients,2017-07-11 06:32:00-04:00,QURE,positive
1061091.0,"UPDATE: uniQure On AMT-060 Says, 'No Activation of T-Cell Responses or Loss of FIX Activity in Any Patient Up To 18 Months'",2017-07-10 12:47:00-04:00,QURE,negative
1061092.0,"UPDATE: uniQure On AMT-060 Says, 'Second-dose Cohort Demonstrates Dose Response Up to One Year, with 84% Reduction in Spontaneous Bleeds and All Patients Free of Prophylactic FIX Replacement Therapy'",2017-07-10 12:47:00-04:00,QURE,positive
1061093.0,"UPDATE: uniQure On AMT-060 Data, Says 'Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Months of Follow-Up'",2017-07-10 12:46:00-04:00,QURE,positive
1061094.0,"uniQure Issues Updated, Long-Term Data From Ongoing Phase I/II Trial Of AMT-060 In Patients with Severe Hemophilia B",2017-07-10 12:46:00-04:00,QURE,negative
1061095.0,A Barrage Of Biotech Updates Expected At ISTH Meeting,2017-07-07 17:08:00-04:00,QURE,neutral
1061096.0,uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates,2017-05-11 07:04:00-04:00,QURE,positive
1061097.0,uniQure Offers New Data on AAV5 Vector: 'Strong Dose-Dependent Transduction in All Animals Tested Regardless of the Level of Anti-AAV5 Antibodies at Pre-Administration',2017-05-10 07:13:00-04:00,QURE,positive
1061098.0,uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates,2017-05-10 07:05:00-04:00,QURE,positive
1061099.0,"uniQure Q1 EPS $(0.80) vs $(0.66) Est, Sales $3.32M vs $6.32M Est",2017-05-09 07:01:00-04:00,QURE,neutral
1061100.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-04-25 08:21:00-04:00,QURE,neutral
1061101.0,uniQure Reports Received EMA Priority Medicines Designation for AMT-060 in Hemophilia B,2017-04-25 07:06:00-04:00,QURE,neutral
1061102.0,UPDATE: uniQure Says Sees Reducing Further Expenses Related to Product by ~$2M Annually Beginning in 2018,2017-04-20 07:07:00-04:00,QURE,neutral
1061103.0,uniQure Says Will Not Seek Marketing Authorization Renewal for Glybera in Europe,2017-04-20 07:06:00-04:00,QURE,neutral
1061104.0,uniQure Publishes Data in Gene Therapy Demonstrating Wide Distribution of AAV5 in the Central Nervous System,2017-04-04 07:52:00-04:00,QURE,negative
1061105.0,"uniQure Q4 EPS $(0.58) vs $(0.59) Est, Sales $25.1M vs $5.8M Est",2017-03-15 07:04:00-04:00,QURE,neutral
1061106.0,25 Stocks Moving In Monday's Pre-Market Session,2017-01-30 08:28:00-05:00,QURE,neutral
1061107.0,uniQure Reports FDA Breakthrough Therapy Designation for AMT-060 in Hempohilia B,2017-01-30 07:03:00-05:00,QURE,neutral
1061108.0,"uniQure Announces Matthew Kapusta CEO, Previously Interim CEO",2016-12-19 07:05:00-05:00,QURE,neutral
1061109.0,"UniQure Vs. Spark Therapeutics: One Has Better Timing, The Other Has Better Efficacy",2016-12-05 13:15:00-05:00,QURE,positive
1061110.0,uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B at ASH 2016,2016-12-03 18:58:00-05:00,QURE,negative
1061111.0,"American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4",2016-12-02 10:53:00-05:00,QURE,neutral
1061112.0,7 Biggest Price Target Changes For Tuesday,2016-11-22 12:13:00-05:00,QURE,neutral
1061113.0,"uniQure Q3 EPS EUR 0.54, Revenue EUR 3.15M",2016-11-22 07:01:00-05:00,QURE,neutral
1061114.0,"Jefferies Downgrades uniQure to Hold, Lowers Target to $8.00",2016-11-22 05:40:00-05:00,QURE,negative
1061115.0,PiperJaffray Downgrades uniQure N.V. - Ordinary Shares to Neutral,2016-11-16 09:30:00-05:00,QURE,positive
1061116.0,"uniQure Completes Strategic Review, Will Focus on Late-Stage Development of Hemophilia B",2016-11-15 07:11:00-05:00,QURE,neutral
1061117.0,"Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure",2016-10-11 08:23:00-04:00,QURE,positive
1061118.0,uniQure Reports Resignation of CEO Daniel Soland; CFO Matthew Kapusta Named as Interim Replacement,2016-09-22 16:21:00-04:00,QURE,negative
1061119.0,uniQure Receives NASDAQ Deficiency Letter Related to Board Composition,2016-09-16 07:16:00-04:00,QURE,neutral
1061120.0,"uniQure Reports Q2 EPS $(0.87) vs $(0.89) Est., Total Sales $1.615M",2016-08-25 16:06:00-04:00,QURE,neutral
1061121.0,Benzinga's Top Initiations,2016-08-04 09:34:00-04:00,QURE,positive
1061122.0,H.C. Wainwright Assumes uniQure at Buy,2016-08-04 07:07:00-04:00,QURE,neutral
1061123.0,"uniQure Says 4 Patient Remain Free of Prophylactic FIX Infusions, Achieving 82% Reduction in total FIX Usage",2016-07-27 14:29:00-04:00,QURE,positive
1061124.0,uniQure Announces Oral Presentation of Updated Results for AMT-060 at WFH 2016 World Congress,2016-07-11 14:01:00-04:00,QURE,neutral
1061125.0,uniQure Announces Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity,2016-06-11 08:38:00-04:00,QURE,neutral
1061126.0,UniQure Reports Q1 Loss/Share €(0.83); Revenue €3.902M,2016-05-31 05:07:00-04:00,QURE,neutral
1061127.0,"uniQure Nominates Jake Kaye To Board, Proposes Corp. Governance Changes",2016-05-09 16:53:00-04:00,QURE,neutral
1061128.0,"uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT",2016-05-09 05:03:00-04:00,QURE,neutral
1061130.0,uniQure Reports Preclinical PoC for Gene Therapy Approach in Huntington's Disease,2016-03-22 11:09:00-04:00,QURE,neutral
1061131.0,uniQure Announces First Patient Dosed in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial,2016-03-14 06:02:00-04:00,QURE,neutral
1061132.0,HC Wainwright Assumes Buy On uniQuire N. V. With $30 PT,2016-02-24 07:04:00-05:00,QURE,neutral
1061133.0,Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data,2016-01-07 15:02:00-05:00,QURE,positive
1061134.0,Shares Of Uniqure NV Surge Following Release Of Clinical Trial Data,2016-01-07 10:43:00-05:00,QURE,positive
1061135.0,Benzinga's Volume Movers,2016-01-07 10:14:00-05:00,QURE,neutral
1061136.0,Benzinga's Top #PreMarket Gainers,2016-01-07 08:23:00-05:00,QURE,positive
1061137.0,uniQure +21.4% Premarket @$18.10; Co Announced Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Tria,2016-01-07 07:28:00-05:00,QURE,neutral
1061138.0,uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial,2016-01-07 06:00:00-05:00,QURE,neutral
1061139.0,"uniQure Announces Conference Call, Will Discuss Low-Dose Cohor In Hemophilia B Phase I/II Gene Therapy Clinical Trial",2016-01-06 16:16:00-05:00,QURE,neutral
1061140.0,"Uniqure Announces Dan Soland CEO, Was Previously COO",2015-12-18 06:35:00-05:00,QURE,neutral
1061141.0,uniQure Names Dan Soland as CEO,2015-12-18 06:35:00-05:00,QURE,neutral
1061142.0,"UPDATE: Chardan's Amusa Notes uniQure 'would not pursue regulatory approval for Glybera in the US, confirming a positive for us...'",2015-12-01 08:43:00-05:00,QURE,positive
1061143.0,"Chardan Capital Says Buy uniQure 'on the market's -17% reaction to old or expected news'; Reiterates Buy Rating, $40 Target",2015-12-01 08:29:00-05:00,QURE,neutral
1061144.0,UPDATE: uniQure Reports Q3 Revs $3.15M Vs Est $2.80M,2015-11-30 07:32:00-05:00,QURE,neutral
1061145.0,uniQure Reports Q3 EPS EUR(0.67) Vs Est EUR$(0.66),2015-11-30 07:31:00-05:00,QURE,neutral
1061146.0,"Earnings Scheduled For November 30, 2015",2015-11-30 04:05:00-05:00,QURE,neutral
1061147.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,QURE,neutral
1061148.0,Morning Market Gainers,2015-09-21 09:42:00-04:00,QURE,neutral
1061149.0,Benzinga's Top #PreMarket Gainers,2015-09-21 08:15:00-04:00,QURE,positive
1061150.0,uniQure +15% Following Saturday Announcement of Positive Topline Results from Phase I/II Trial in Sanfilippo B Syndrome Patients Using AAV5-Based Gene Therapy,2015-09-21 07:26:00-04:00,QURE,positive
1061151.0,uniQure Announces Positive Topline Results from Phase I/II Trial in Sanfilippo B Syndrome Patients Using AAV5-Based Gene Therapy,2015-09-19 08:55:00-04:00,QURE,positive
1061152.0,Benzinga's Volume Movers,2015-09-18 10:23:00-04:00,QURE,neutral
1061153.0,uniQure Reports Q2 Loss/Share €(0.87); Revenue €1.615M,2015-08-27 05:11:00-04:00,QURE,neutral
1061154.0,Market Panic Has Created 'Compelling' Opportunities In Biotech,2015-08-25 13:06:00-04:00,QURE,positive
1061155.0,"Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics",2015-08-25 09:13:00-04:00,QURE,positive
1061156.0,uniQure Receives Additional $53M from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment,2015-08-10 05:03:00-04:00,QURE,neutral
1061157.0,Benzinga's Top Initiations,2015-08-07 10:01:00-04:00,QURE,positive
1061158.0,"WallachBeth Initiates Coverage on uniQure at Buy, Announces $35.00 PT",2015-08-07 07:30:00-04:00,QURE,neutral
1061159.0,Roth Capital's Chattopadhyay Sees 'Compelling Entry Point' in Shares of uniQure,2015-07-16 09:04:00-04:00,QURE,positive
1061160.0,"Cowen Starts Uniqure At Outperform, Sees Hemophilia As 'Most Significant' Near-Term Catalyst",2015-07-15 10:36:00-04:00,QURE,positive
1061161.0,Cowen & Company Initiates Coverage on uniQure at Outperform,2015-07-15 07:40:00-04:00,QURE,neutral
1061162.0,uniQure Report Closing of Strategic Partnership with Bristol-Myers Squibb to Develop  Cardiovascular Disease  Gene Therapies,2015-05-26 09:30:00-04:00,QURE,neutral
1061163.0,2 Gene Therapy Stocks Oppenheimer Just Said Will 'Outperform',2015-05-22 09:10:00-04:00,QURE,neutral
1061164.0,Benzinga's Top Initiations,2015-05-22 08:54:00-04:00,QURE,positive
1061165.0,Oppenheimer Initiates Uniqure With Outperform,2015-05-22 08:09:00-04:00,QURE,neutral
1061166.0,"Oppenheimer Initiates Coverage on uniQure at Outperform, Announces $47.00 PT",2015-05-22 06:39:00-04:00,QURE,neutral
1061167.0,"uniQure Reports Q1 Loss $0.30 Vs Exp Loss $0.31, Sales $4.01M",2015-05-12 16:01:00-04:00,QURE,negative
1061168.0,"6-K from uniQure Shows Committee for Advanced Therapies Has Requested Supplemental Info Related to Glybera, Co. Continues to Suggest Data of Glybera Supports Efficacy",2015-05-05 11:21:00-04:00,QURE,positive
1061169.0,Adam Feuerstein @adamfeuerstein Tweet: From last night --> Gene Therapy Stocks on Watch Following Failure of $CLDN Heart Failure Trial thestreet.com/story/13126476… $BLUE $QURE $ONCE,2015-04-27 06:37:00-04:00,QURE,negative
1061170.0,Benzinga's Top Initiations,2015-04-24 09:58:00-04:00,QURE,positive
1061171.0,Chardan Capital Initiates UniQure At Buy,2015-04-24 09:06:00-04:00,QURE,neutral
1061172.0,"Chardan Capital Initiates Coverage on uniQure at Buy, Announces $40.00 PT",2015-04-24 08:08:00-04:00,QURE,neutral
1061173.0,"BMO Capital Initiates Coverage on uniQure at Outperform, Announces $49.00 PT",2015-04-22 17:21:00-04:00,QURE,neutral
1061174.0,Benzinga's Volume Movers,2015-04-13 10:25:00-04:00,QURE,neutral
1061175.0,Morning Market Losers,2015-04-10 09:48:00-04:00,QURE,negative
1061176.0,Benzinga's Top #PreMarket Losers,2015-04-10 08:26:00-04:00,QURE,negative
1061177.0,uniQure Prices 3M Share Offering @$29.50/Share,2015-04-10 04:40:00-04:00,QURE,positive
1061178.0,Morning Market Losers,2015-04-09 09:52:00-04:00,QURE,negative
1061179.0,Benzinga's Top #PreMarket Losers,2015-04-09 08:16:00-04:00,QURE,negative
1061180.0,"uniQure Announces Launch of Follow-on Public Offering, 3M Shares",2015-04-07 16:30:00-04:00,QURE,positive
1061181.0,Benzinga's Volume Movers,2015-04-06 10:16:00-04:00,QURE,neutral
1061182.0,Stocks Hitting 52-Week Highs,2015-04-06 10:04:00-04:00,QURE,neutral
1061183.0,Morning Market Gainers,2015-04-06 09:41:00-04:00,QURE,neutral
1061184.0,UPDATE: uniQure Share Rise 53% Premarket Following Announcement of Deal With Bristol-Myers Squibb,2015-04-06 08:27:00-04:00,QURE,positive
1061185.0,"uniQure Reports Q4 Earnings from Licensing, Collaboration Sales €1.5M, FY14 Loss of €2.16/Share",2015-04-06 08:21:00-04:00,QURE,negative
1061186.0,Benzinga's Top #PreMarket Gainers,2015-04-06 08:05:00-04:00,QURE,positive
1061187.0,"uniQure Share Rise 14% Premarket on Light Trading, Following Announcement of Deal With Bristol-Myers Squibb,",2015-04-06 07:38:00-04:00,QURE,positive
1061188.0,"UPDATE: uniQure to Receive $50M Upfront Payment at Close of Transaction; Bristol-Myers-Squibb to Acquire Additional 5% Ownership Before December 31, 2015 at 10% Premium",2015-04-06 07:37:00-04:00,QURE,neutral
1061189.0,"Bristol-Myers Squibb, uniQure Report Deal Providing Bristol Exclusive Access to uniQure's Gene Therapy Technology Platform for Multiple Targets in CV Diseases",2015-04-06 07:33:00-04:00,QURE,positive
1061190.0,"uniQure N.V Reports FY 2014 EPS $3.28, Sales $28.4M, No Estimates Available",2015-03-12 16:20:00-04:00,QURE,negative
1061191.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,QURE,neutral
1061192.0,Filing from uniQure Shows Registration for $250M Mixed Securities Shelf Offering,2015-03-03 09:12:00-05:00,QURE,positive
1061193.0,Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year,2015-01-20 16:21:00-05:00,QURE,neutral
1061194.0,"Treeway Announces License, Collaboration Agreement With uniQure",2015-01-14 08:36:00-05:00,QURE,positive
1061195.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,QURE,neutral
1061196.0,uniQure Announces Acquisition of Cardiology Gene Therapy For EU3 Million,2014-08-11 16:36:00-04:00,QURE,neutral
1061197.0,Uniqure Says Expects to Launch Glybera in Q4 2014/Q1 2015 ,2014-08-04 07:13:00-04:00,QURE,neutral
1061198.0,uniQure Closes on Additional $10M Venture Loan from Hercules Capital ,2014-07-01 05:27:00-04:00,QURE,neutral
1061199.0,"uniQure Six Year FOllow-Up Results for Glybera Positive, 40-50% Lower Post Treatment Pancreatitis Events",2014-06-03 11:18:00-04:00,QURE,positive
1061200.0,uniQure Offers Analysis of Six-Year Follow-Up Data for Glybera,2014-06-03 11:16:00-04:00,QURE,neutral
1061201.0,"uniQure, Medison Sign Glybera Distribution Agreement for Israel ",2014-05-29 05:27:00-04:00,QURE,positive
1061202.0,uniQure Announces Successful Transfection of Liver Cells with AAV5 and Strong Safety Data from Acute Intermittent Porphyria Clinical Trial ,2014-05-27 05:24:00-04:00,QURE,positive
1061203.0,UPDATE: uniQure Initiates Search for New COO,2014-04-09 07:08:00-04:00,QURE,neutral
1061204.0,uniQure  Names Eric Goossens as New COO,2014-04-09 07:07:00-04:00,QURE,neutral
1061205.0,"Piper Jaffray Initiates Coverage on uniQure BV at Overweight, Announces $35.00 PT",2014-03-03 08:47:00-05:00,QURE,negative
1061206.0,"Leerink Swann Initiates Coverage on uniQure BV at Outperform, Announces $25.00 PT",2014-03-03 08:47:00-05:00,QURE,neutral
1061207.0,"Jefferies Initiates Coverage on uniQure BV at Buy, Announces $24.00 PT",2014-03-03 07:36:00-05:00,QURE,neutral
1061208.0,Shares of uniQure Open for Trade at $17 After Price at $17/Share,2014-02-05 10:51:00-05:00,QURE,positive
1061209.0,Waiting on IPO Opens for:,2014-02-05 10:25:00-05:00,QURE,neutral
1061210.0,uniQure Sets IPO of 4.6M Shares at $13-15/Share,2014-01-24 08:57:00-05:00,QURE,positive
1061211.0,"Uniqure BV Files $75M IPO, Expects to List on NASDAQ Under 'QURE'",2014-01-02 11:48:00-05:00,QURE,neutral
